Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 405 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Constipation Clear all
Not listed Phase 3 Interventional

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit

NCT01050595
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone Bromide, Placebo-Normal Saline
Drug
Lead sponsor
St. John Health System, Michigan
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 3 Interventional

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

NCT00256932
View directory record Official record
Conditions
Bowel Dysfunction, Constipation
Interventions
alvimopan, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
137
States / cities
Birmingham, Alabama • Calera, Alabama • Muscle Shoals, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

NCT00529087
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 20, 2026, 5:24 PM EDT
Recruiting Not applicable Interventional

Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation

NCT03687814
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Low FODMAP diet/PEG 3350, sham diet/PEG 3350
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Not applicable Interventional Results available

Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation

NCT00662363
View directory record Official record
Conditions
Constipation
Interventions
Lubiprostone, Senna
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 3 Interventional

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01427283
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
149
States / cities
Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of a Butyrate-Polyphenol Formulation on Gut Health and Associated Symptoms

NCT07371975
View directory record Official record
Conditions
Gut Health
Interventions
Butyrate + Polyphenol Formulation, Placebo
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
25 Years to 70 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 4 Interventional

A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children

NCT00319670
View directory record Official record
Conditions
Constipation
Interventions
MiraLax
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
4 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Boston, Massachusetts • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Results available

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

NCT00672139
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Mobile, Alabama • Laguna Hills, California • Lancaster, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans

NCT01500317
View directory record Official record
Conditions
Effects of 2 Mu-opiates on Gastrointestinal Transit
Interventions
Tapentadol, Oxycodone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01395524
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
90
States / cities
Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 20, 2026, 5:24 PM EDT
Not listed Phase 4 Interventional

Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome

NCT01312259
View directory record Official record
Conditions
Painful Bladder Syndrome, Interstitial Cystitis, Pelvic Floor; Insufficiency, Bowel Dysfunction, Sexual Dysfunction, Pelvic Floor; Incompetency
Interventions
Changing the Interstim parameter of '' Frequency" in patients with Interstitial Cystitis
Other
Lead sponsor
Pelvic and Sexual Health Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

Lubiprostone Effects on Visceral Pain Sensitivity

NCT01166789
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT01880424
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Placebo, Linaclotide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
52
States / cities
Huntsville, Alabama • North Little Rock, Arkansas • Phoenix, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Results available

Effect of Octreotide on the Colonic Motility in Pediatric Patients

NCT01917773
View directory record Official record
Conditions
Colonic Motility Index, Constipation
Interventions
Octreotide, Bisacodyl
Drug
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

NCT04110145
View directory record Official record
Conditions
Functional Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 5 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Not applicable Interventional

Performance, Efficacy and Safety of Vibrating Capsule in Aiding Constipated Individuals

NCT02030756
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
vibrating capsule, sham non-vibrating capsule
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chevy Chase, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Not applicable Interventional

Effects of Constipation Treatment in Chronic Kidney Disease: A Pilot Feasibility Trial

NCT06123195
View directory record Official record
Conditions
Chronic Kidney Disease, Constipation
Interventions
Constipation treatment
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 20, 2026, 5:24 PM EDT
Withdrawn Not applicable Interventional

The Impact of Aerobic Interval and Inspiratory Muscle Training On Patient Reported Outcome Scores In Individuals With Chronic Constipation

NCT05321953
View directory record Official record
Conditions
Constipation, Constipation by Outlet Obstruction, Constipation-predominant Irritable Bowel Syndrome, Constipation - Functional
Interventions
Standard Physical Therapy Care, Aerobic and Inspiratory Muscle Training
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 20, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

NCT07723924
View directory record Official record
Conditions
Functional Constipation (FC)
Interventions
plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 2 Interventional

A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults

NCT00583154
View directory record Official record
Conditions
Constipation
Interventions
BLI-801
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Anaheim, California • Cranston, Rhode Island • Cumberland, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Not applicable Interventional Results available

Compassionate Use Study of Methylnaltrexone

NCT01368562
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

NCT01443403
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Placebo, Naldemedine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
49
States / cities
Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 20, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

NCT01053962
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg, SP-304 9.0 mg, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
14
States / cities
Mesa, Arizona • Tucson, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 20, 2026, 5:24 PM EDT